Compare ABNB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABNB | REGN |
|---|---|---|
| Founded | 2008 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4B | 79.3B |
| IPO Year | 2020 | 1991 |
| Metric | ABNB | REGN |
|---|---|---|
| Price | $131.07 | $733.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 24 |
| Target Price | $148.21 | ★ $799.33 |
| AVG Volume (30 Days) | ★ 4.2M | 826.1K |
| Earning Date | 02-12-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.47% |
| EPS Growth | ★ 47.91 | 2.88 |
| EPS | 4.19 | ★ 41.59 |
| Revenue | $11,943,000,000.00 | ★ $14,247,800,000.00 |
| Revenue This Year | $11.79 | $2.08 |
| Revenue Next Year | $9.99 | $6.82 |
| P/E Ratio | $31.62 | ★ $17.84 |
| Revenue Growth | ★ 10.18 | 2.89 |
| 52 Week Low | $99.88 | $476.49 |
| 52 Week High | $163.93 | $821.11 |
| Indicator | ABNB | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 40.60 |
| Support Level | $130.15 | $743.94 |
| Resistance Level | $141.40 | $766.64 |
| Average True Range (ATR) | 3.53 | 20.38 |
| MACD | -1.14 | -8.52 |
| Stochastic Oscillator | 9.44 | 3.37 |
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency; it also offers booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Dec. 31, 2024. Listings from the company's 5 million-plus hosts are spread over almost every country in the world. In 2024, 45% of revenue was from North America, 37% from Europe, the Middle East, and Africa, 9% from Latin America, and 9% from Asia-Pacific. Transaction fees for online bookings account for all its revenue.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).